Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Nucl Med Commun ; 41(11): 1153-1160, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32796448

ABSTRACT

OBJECTIVES: The aim of this study was to investigate the sentinel lymph node biopsy (SLNB) method in patients with cancer of the oesophagus or gastro-oesophageal junction (GOJ) guided by preoperative hybrid single-photon emission tomography/computed tomography (SPECT/CT) lymphoscintigraphy. METHODS: Thirty-nine patients with stage T1-T3, any N-stage, M0 cancer of the oesophagus or GOJ planned for curatively intended esophagectomy underwent preoperative SPECT/CT lymphoscintigraphy following endoscopically guided submucosal injection of radiocolloid and intraoperative radio-guided SLNB using a hand-held gamma scintillation device. RESULTS: The detection rate in preoperative SPECT/CT imaging was 88%. The median number of detected SLN stations in preoperative imaging was 1 (range 0-4). At least one suspected SLN was identified in all intraoperative SLNP procedures. In six cases, no lymph nodes were identified in the SLNB. In six cases, the SLNB was false negative. The sensitivity for successful SLNB procedures was 20%, the specificity was 100% and the accuracy was 75%. CONCLUSIONS: Preoperative SLN mapping using SPECT/CT yields a high number of detected SLN stations compared to previous studies using planar imaging. The accuracy of the SLNB method in patients with predominantly ≥T3-stage tumours and with a history of previous neoadjuvant treatment is poor, and the method is not recommended in these patient groups.


Subject(s)
Esophageal Neoplasms/diagnostic imaging , Esophageal Neoplasms/pathology , Esophagogastric Junction/pathology , Preoperative Period , Sentinel Lymph Node Biopsy , Single Photon Emission Computed Tomography Computed Tomography , Adult , Aged, 80 and over , Esophageal Neoplasms/surgery , Esophagogastric Junction/diagnostic imaging , Female , Humans , Male , Middle Aged , Neoplasm Staging , Sensitivity and Specificity
2.
Cancer Imaging ; 18(1): 53, 2018 Dec 18.
Article in English | MEDLINE | ID: mdl-30563571

ABSTRACT

BACKGROUND: In current best practise, curatively intended treatment for oesophageal cancer usually consists of neoadjuvant chemo-radiotherapy (nCRT) or perioperative chemotherapy, and oesophagectomy. Sentinel Lymph Node Biopsy (SLNB) has the potential to identify patients without lymph node metastases and thus improve the staging accuracy and influence treatment. The impact of neoadjuvant treatment on the lymphatic drainage of oesophageal cancers and subsequently the SLNB procedure in this tumour type has previously not been well studied. PURPOSE: To evaluate changes in lymphatic drainage patterns of the tumour in patients with cancer of the oesophagus or gastro-oesophageal junction (GOJ) using Sentinel Lymph Node (SLN) hybrid SPECT/CT lymphoscintigraphy before and after nCRT. METHODS: Patients with clinical stage T2-T3, any N-stage, M0 cancer of the oesophagus or GOJ underwent endoscopically guided peri-/intratumoral injection of radio-colloid followed by hybrid SPECT/CT lymphoscintigraphy prior to, and once again following, nCRT. SPECT/CT images were evaluated to number and location of SLNs and compared between the two examinations. RESULTS: Ten patients were included in this pilot trial. SPECT/CT lymphoscintigraphy was performed in twenty procedures. The same Sentinel Lymph Node station before and after nCRT was observed in one single patient. In two patients, no SLN was detected before nCRT. In three patients no SLN was detected following nCRT. In four patients, the SLN stations were not the same station at baseline compared to follow-up examination. CONCLUSIONS: The reproducibility SLN detection in patients with cancer of the oesophagus/GOJ following nCRT was very poor. nCRT appears to alter lymphatic drainage patterns and thus may affect detection of SLNs and potentially also the accuracy of an SLNB in these patients. On the basis of these initial results, we abort further patient recruitment in our institution. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR). Identifier ACTRN12618001433291 . Date registered: 27/08/2018. Retrospectively registered.


Subject(s)
Esophageal Neoplasms/diagnostic imaging , Esophageal Neoplasms/pathology , Esophagogastric Junction/diagnostic imaging , Lymphoscintigraphy , Sentinel Lymph Node/diagnostic imaging , Single Photon Emission Computed Tomography Computed Tomography , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Chemoradiotherapy , Cisplatin/administration & dosage , Colloids/administration & dosage , Esophageal Neoplasms/therapy , Esophagectomy , Esophagogastric Junction/pathology , Esophagoscopy , Female , Fluorouracil/administration & dosage , Humans , Injections, Intralesional , Injections, Intralymphatic , Lymphatic Metastasis , Male , Middle Aged , Neoadjuvant Therapy , Organoplatinum Compounds/administration & dosage , Pilot Projects , Pyridines/administration & dosage , Radiopharmaceuticals/administration & dosage , Reproducibility of Results , Retrospective Studies , Sentinel Lymph Node Biopsy/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...